• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Aditxt Appoints Corinne Pankovcin as President and Thomas J. Farley as Chief Financial Officer as Company Prepares for Global Commercialization

    9/27/21 8:45:00 AM ET
    $ADTX
    $BKCC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Finance: Consumer Services
    Finance
    Get the next $ADTX alert in real time by email

    Aditxt, Inc. ("Aditxt, or the "Company"). (NASDAQ:ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced key executive management changes to support its growth plans. Corinne Pankovcin, who has served as CFO of Aditxt, has been appointed as President and will work closely with the Company's CEO, Amro Albanna, to execute Aditxt's business strategy. Thomas J. Farley, who has served as Controller and Principal Accounting Officer of Aditxt, has been appointed as CFO.

    As CFO of Aditxt since July 2020, Ms. Pankovcin, along with the Company's CEO and executive team, has effectively managed the Company's growth as it became publicly traded on Nasdaq. Previously, she served as CFO and Treasurer of world-class organizations including Business Development Corporation of America and Blackrock Capital Investment Corporation (NASDAQ:BKCC), as well as Managing Director of Finance at BlackRock Investment Management LLC. Prior to joining BlackRock, Ms. Pankovcin was CFO for the Global Emerging Markets products group at AIG Capital Partners. Ms. Pankovcin began her career with PricewaterhouseCoopers LLP, where she ultimately held the role of Senior Manager of Business Assurance for Consumer Products, Manufacturing, and Middle Market industries. Ms. Pankovcin earned her B.S. in Accounting from Dowling College and her Master's Degree in Business Administration from Hofstra University. She is a Certified Public Accountant.

    Serving as Controller since October 2020 and Principal Accounting Officer since March 2021 at Aditxt, Mr. Farley worked closely with Ms. Pankovcin on all aspects of public company management and SEC reporting. Prior to joining Aditxt, Mr. Farley was the Senior Controller and Treasurer of Business Development Corporation of America and was the Senior Controller of Blackrock Capital Investment Corporation (NASDAQ:BKCC). Before joining BlackRock, Mr. Farley was a Senior Controller for PineBridge Investments. He began his career with PricewaterhouseCoopers LLP. Mr. Farley earned his B.S. in Accounting from Long Island University. He is a Certified Public Accountant.

    "As Aditxt grows and positions toward a global footprint, we are fortunate to have internal management talent who can move into key executive positions ready to implement our growth strategy. Corinne has proved her business acumen and effectiveness through our Nasdaq listing and beyond. As President, she'll work closely with me on all aspects of our business' scaleup across the board," stated Aditxt Co-Founder, Chairman, and CEO Amro Albanna. "We are very fortunate to have Tom, who is extremely well qualified, to step into the CFO role based on his extensive experience in financial management of publicly traded companies and in auditing companies including the biopharma sector. I look forward to working with both Corinne and Tom in their new roles."

    About Aditxt:

    Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. Aditxt's immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. Aditxt's immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com

    Forward-Looking Statements

    Certain statements in this press release constitute "forward-looking statements" within the meaning of federal securities laws. Forward looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company's ongoing and planned product and business development; the Company's intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section titled "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20210927005469/en/

    Get the next $ADTX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ADTX
    $BKCC

    CompanyDatePrice TargetRatingAnalyst
    BlackRock Capital Investment Corporation
    $BKCC
    4/18/2023$4.25 → $3.00Overweight → Equal Weight
    Wells Fargo
    BlackRock Capital Investment Corporation
    $BKCC
    10/25/2021$4.25 → $4.50Overweight
    Wells Fargo
    BlackRock Capital Investment Corporation
    $BKCC
    8/9/2021$4.00 → $4.25Overweight
    Wells Fargo
    More analyst ratings

    $ADTX
    $BKCC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Hrt Financial Lp bought $23,454 worth of Class A Shares (15,636 units at $1.50) and sold $29,875 worth of Class A Shares (25,534 units at $1.17), closing all direct ownership in the company (SEC Form 4)

      4 - Aditxt, Inc. (0001726711) (Issuer)

      10/17/24 1:58:54 PM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADTX
    $BKCC
    SEC Filings

    See more
    • Aditxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Aditxt, Inc. (0001726711) (Filer)

      7/1/25 4:30:32 PM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Aditxt Inc.

      EFFECT - Aditxt, Inc. (0001726711) (Filer)

      7/1/25 12:15:05 AM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Aditxt Inc.

      424B3 - Aditxt, Inc. (0001726711) (Filer)

      6/30/25 5:04:27 PM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADTX
    $BKCC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Pelletier Saundra L

      3 - Aditxt, Inc. (0001726711) (Issuer)

      6/9/25 5:56:40 PM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Hrt Financial Lp bought $23,454 worth of Class A Shares (15,636 units at $1.50) and sold $29,875 worth of Class A Shares (25,534 units at $1.17), closing all direct ownership in the company (SEC Form 4)

      4 - Aditxt, Inc. (0001726711) (Issuer)

      10/17/24 1:58:54 PM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Hrt Financial Lp claimed ownership of 25,434 units of Class A Shares (SEC Form 3)

      3 - Aditxt, Inc. (0001726711) (Issuer)

      10/17/24 1:31:48 PM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADTX
    $BKCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Aditxt Inc. (Amendment)

      SC 13G/A - Aditxt, Inc. (0001726711) (Subject)

      2/14/24 2:14:47 PM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by BlackRock Capital Investment Corporation (Amendment)

      SC 13G/A - BlackRock Capital Investment Corp (0001326003) (Subject)

      2/13/24 4:03:54 PM ET
      $BKCC
      Finance: Consumer Services
      Finance
    • SEC Form SC 13G/A filed by Aditxt Inc. (Amendment)

      SC 13G/A - Aditxt, Inc. (0001726711) (Subject)

      2/6/24 10:06:47 AM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADTX
    $BKCC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting

      -- BV Market Projected to Reach $1.0 Billion in the U.S. by 2033 -- -- BV Affects 21 Million U.S. Women; As many as 50% Experience Recurrent BV Within Six Months of Treatment -- SAN DIEGO, June 11, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM) today announced that a study of SOLOSEC® (secnidazole) 2 g oral granules for recurrent bacterial vaginosis (BV) presented at the 2025 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting supports further development of SOLOSEC for the management of recurrent BV, a potential new indication. EVFM) (PRNews

      6/11/25 8:14:00 AM ET
      $ADTX
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

      Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc. (OTCPK: EVFM) ("Evofem"), to Aditxt's Board of Directors. "We believe that Saundra's background as a CEO and entrepreneur, coupled with her deep industry expertise and knowledge, will complement our current Board well. We look forward to her contributions at this critical stage as we seek to execute our growth strategy for the overall business, transition Aditxt to a commercial stage company, and advance our plans to build a vertical focus on monitoring, prevention and treatment

      6/9/25 8:15:00 AM ET
      $ADTX
      $WINT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6

      Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt"), a social innovation platform accelerating promising health innovations, today announced that its CEO Amro Albanna will be joined for tomorrow's Aditxt Weekly Update by Dr. Friedrich Kapp, Chris Mitton, and Evofem Biosciences' CEO Saundra Pelletier to discuss progress in immune therapy, early disease detection and women's health, respectively. Event Details: Title: Aditxt Weekly Update Date: Friday, June 6, 2025 Time: 11:30 a.m. ET Location: Virtual (Zoom) Registration: Click here to register Friedrich Kapp, M.D, Ph.D. is co-CEO of Adimune, Inc.("Adimune"), which is advancing its lead therapeutic candidate ADI-100™ towards an Investigational New Dru

      6/5/25 8:15:00 AM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADTX
    $BKCC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BlackRock Capital downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded BlackRock Capital from Overweight to Equal Weight and set a new price target of $3.00 from $4.25 previously

      4/18/23 7:50:25 AM ET
      $BKCC
      Finance: Consumer Services
      Finance
    • Wells Fargo reiterated coverage on BlackRock Capital Inv with a new price target

      Wells Fargo reiterated coverage of BlackRock Capital Inv with a rating of Overweight and set a new price target of $4.50 from $4.25 previously

      10/25/21 8:21:55 AM ET
      $BKCC
      Finance: Consumer Services
      Finance
    • Wells Fargo reiterated coverage on BlackRock Capital Inv with a new price target

      Wells Fargo reiterated coverage of BlackRock Capital Inv with a rating of Overweight and set a new price target of $4.25 from $4.00 previously

      8/9/21 7:05:20 AM ET
      $BKCC
      Finance: Consumer Services
      Finance

    $ADTX
    $BKCC
    Financials

    Live finance-specific insights

    See more
    • Evofem Reports Fourth Consecutive Year of Net Sales Growth

      -- 2024 Net Sales Increased 6% to $19.4 Million -- -- Total Operating Expense Reduced 27% from 2023 Levels, Excluding Non-cash Amortization Expense -- -- Sales and Marketing Expense as a Percentage of Net Sales was 47% for 2024 and 31% for the Fourth Quarter, the Most Favorable Ratios since the PHEXXI Launch -- SAN DIEGO, March 24, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFM), today announced financial results for the fourth quarter and year ended December 31, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:E

      3/24/25 8:30:00 AM ET
      $ADTX
      $EVFM
      $WINT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

      — Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged commercial agreement for Phexxi in Middle East — SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the third quarter and nine-month period ended September 30, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences,

      11/14/24 4:36:00 PM ET
      $ADTX
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evofem Biosciences Announces Financial Results for the Second Quarter of 2024

      — Improved loss from operations by 81% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged ex-U.S. commercial agreement for Phexxi in Middle East — SAN DIEGO, Aug. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the second quarter and first half of 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)">

      8/14/24 7:00:00 AM ET
      $ADTX
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADTX
    $BKCC
    Leadership Updates

    Live Leadership Updates

    See more
    • Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

      Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc. (OTCPK: EVFM) ("Evofem"), to Aditxt's Board of Directors. "We believe that Saundra's background as a CEO and entrepreneur, coupled with her deep industry expertise and knowledge, will complement our current Board well. We look forward to her contributions at this critical stage as we seek to execute our growth strategy for the overall business, transition Aditxt to a commercial stage company, and advance our plans to build a vertical focus on monitoring, prevention and treatment

      6/9/25 8:15:00 AM ET
      $ADTX
      $WINT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

      Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that Dr. Charles Howe, Chair of the Division of Experimental Neurology and Director of Research at the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, will join the Aditxt Weekly Update on May 2, 2025, to discuss key findings from the newly announced preclinical study evaluating ADI-100™, the lead therapeutic candidate developed by its wholly owned subsidiary, Adimune™, Inc. ("Adimune"). Featured participants will include Dr. Shahrokh Shabahang, Chief Innovation Officer of Aditxt, Inc., and Dr. Friedrich Kapp, Co-Chief Executive Offic

      4/17/25 8:15:00 AM ET
      $ADTX
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025

      Event exploring the escalating threat of emerging infectious diseases Discussion covering going-private transaction with Aditxt, strategic growth partner HALIFAX, Nova Scotia, April 02, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI, OTC:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that its President and CEO, Don Cilla, Pharm.D., M.B.A., will join Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt") Co-founder and CEO, Amro Albanna, for the Aditxt Weekly Update on April 4, 2025. The discussion will cover the Company's recent operational highlights, including $117 million in

      4/2/25 8:17:20 AM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care